Security key
87184Q107
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS)
CUSIP: 87184Q107
Q2 2022 13F Holders as of 30 Jun 2022
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 35,563,928
- Total 13F value
- $34,226,317
- Share change
- -9,010,846
- SEC-reported price per share
- $0.96
- Number of holders
- 58
- Value change
- -$9,550,880
- Number of buys
- 26
- Number of sells
- 57
- Shares outstanding
- 27,995,500
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q2 2022
Institutions
58
Top holders
10
SYRS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2022
Previous quarter: Q1 2022
Syros Pharmaceuticals, Inc. SEC filings
Syros Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87184Q107
Recent filing periods:
Ownership snapshot
Top reported holders of SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
31 Mar 2022
13F
Lead comparable stake: 22%
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 22%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Bain Capital Life Sciences Invest...
22%
FMR LLC
20%
BlackRock Finance, Inc.
15%
Artal Group S.A.
13%
Ally Bridge Group (NY) LLC
12%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
22%
|
$7,455,000
6,264,420 shares
|
— | 31 Mar 2022 |
| FMR LLC |
13F
Company
|
20%
|
$6,576,000
5,526,376 shares
|
— | 31 Mar 2022 |
| BlackRock Finance, Inc. |
13F
Company
|
15%
|
$4,963,000
4,170,141 shares
|
— | 31 Mar 2022 |
| Artal Group S.A. |
13F
Company
|
13%
|
$4,165,000
3,500,000 shares
|
— | 31 Mar 2022 |
| Ally Bridge Group (NY) LLC |
13F
Company
|
12%
|
$4,004,000
3,364,895 shares
|
— | 31 Mar 2022 |
| Flagship Pioneering, LLC |
13F
Company
|
10%
|
$3,497,000
2,938,494 shares
|
— | 31 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
58
Shares
35,563,928
Rows available
58
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
86
Q2 2022 holders
58
Holder diff
-28
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 value | Q2 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend